TQ Therapeutics GmbHFresenius Kabi and TQ Therapeutics have entered into a strategic development agreement in cell and gene therapy. Fresenius Kabi receives an exclusive licence to develop, manufacture and distribute products incorporating TQ’s cell selection technology. The aim is to enable more scalable, efficient cell therapy production and broader, more cost-effective patient access.
Tag Archive for: cost-effective
Rezon BioRezon Bio has launched as a European contract development and manufacturing organisation (CDMO) for biologics. The new company has been created following the demerger of Polpharma Biologics into two independent companies.